Citadel Advisors
NBSE

Citadel Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Citadel Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,140
Closed -$9K – 15630
2022
Q3 		$9K Buy
+1,140
New +$18.9K ﹤0.01% 12297
2022
Q1 		– Sell
-1,476
Closed -$51K – 14849
2021
Q4 		$83K Buy
+1,476
New +$99.1K ﹤0.01% 12908
2021
Q3 		– Sell
-1,384
Closed -$106K – 14885
2021
Q2 		$133K Buy
1,384
+698
+102% +$77.1K ﹤0.01% 12643
2021
Q1 		$101K Sell
686
-1,406
-67% -$255K ﹤0.01% 12470
2020
Q4 		$293K Buy
2,092
+755
+56% +$122K ﹤0.01% 9119
2020
Q3 		$203K Sell
1,337
-144
-10% -$23.5K ﹤0.01% 8778
2020
Q2 		$260K Buy
+1,481
New +$248K ﹤0.01% 8143
2020
Q1 		– Sell
-591
Closed -$85K – 10347
2019
Q4 		$85K Buy
+591
New +$69.3K ﹤0.01% 8608
2019
Q1 		– Sell
-478
Closed -$16K – 10026
2018
Q4 		$16K Buy
478
+433
+962% +$31.4K ﹤0.01% 8824
2018
Q3 		$3K Sell
45
-127
-74% -$9.57K ﹤0.01% 9136
2018
Q2 		$14K Buy
172
+60
+54% +$5.24K ﹤0.01% 8702
2018
Q1 		$10K Buy
+112
New +$16.7K ﹤0.01% 8183
2017
Q4 		– Sell
-64
Closed -$18K – 8547
2017
Q3 		$18K Buy
+64
New +$17.5K ﹤0.01% 7379
2017
Q1 		– Sell
-28
Closed -$17K – 8175
2016
Q4 		$17K Sell
28
-11
-28% -$11.6K ﹤0.01% 7117
2016
Q3 		$45K Sell
39
-49
-56% -$52.9K ﹤0.01% 6875
2016
Q2 		$96K Buy
88
+58
+193% +$72.8K ﹤0.01% 6207
2016
Q1 		$39K Buy
30
+19
+173% +$27.1K ﹤0.01% 6312
2015
Q4 		$28K Sell
11
-130
-92% -$200K ﹤0.01% 7717
2015
Q3 		$155K Buy
141
+101
+253% +$117K ﹤0.01% 6473
2015
Q2 		$40K Sell
40
-1
-2% -$1.08K ﹤0.01% 7815
2015
Q1 		$41K Buy
+41
New +$135K ﹤0.01% 7517
2014
Q4 		– Sell
-23
Closed -$68K – 8794
2014
Q3 		$68K Sell
23
-5
-18% -$16.5K ﹤0.01% 6695
2014
Q2 		$106K Buy
+28
New +$105K ﹤0.01% 6182

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CMU
Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Citadel Advisors's NBSE Position: Q4 2022 in Review

Citadel Advisors sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2022, closing a stake of 1,140 shares — an estimated $9K sold.

Citadel Advisors first reported a position in NBSE in Q2 2014 and held it in 23 quarters. The position peaked at $293K in Q4 2020. 34 funds tracked by Wall St. Rank hold NBSE as of Q4 2022.

  • Citadel Advisors reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Citadel Advisors sold 1,140 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $9K.
  • Citadel Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2014 and held it in 23 quarters.
  • Citadel Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $293K in Q4 2020.
  • 34 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.